p-Synuclein-α (S129) Peptide 
Datasheet
COA
MSDS
SHIP
Product Name :
p-Synuclein-α (S129) Peptide Applications :
Blocking Background :
The synuclein family members, including α-synuclein (also designated NACP for non-β Amyloid component) and β-synuclein, are predominantly expressed in the brain and are speculated to be involved in synaptic regulation and neuronal plasticity. α-synuclein is localized to neuronal cell bodies and synapses. α-synuclein was first identified as a component of Alzheimer’s disease amyloid plaques. Abnormal platelet function in Alzheimer’s disease has been demonstrated. During megakaryocytic differentiation α-synuclein has been found to be upregulated, while β-synuclein is downregulated, indicating that coordinate expression of synucleins may be important during hematopoetic cell differentiation. A mutant form of α-synuclein has been found in patients with early onset Parkinson’s disease. Alternative Name :
Alpha synuclein , Alpha-synuclein , Alpha-synuclein, isoform NACP140 , alphaSYN , PARK 1 , PARK 4 , PARK1 , PARK4 , Parkinson disease (autosomal dominant, Lewy body) 4 , Parkinson disease familial 1 , PD 1 , PD1 , SNCA , Snca synuclein, alpha (non A4 component of amyloid precursor) , Synuclein alpha 140 , Synuclein alpha , Swiss-Prot :
P37840 Product :
1 mg/ml in DI water. Purification&Purity :
Synthetic peptide p-Synuclein-α (S129). (Note: the amino acid sequence is proprietary). The purity is > 98%. Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
This peptide can be used with studies using BS4361 p-Synuclein-α (S129) pAb.
p-Synuclein-α (S129) Peptide Applications :
Blocking Background :
The synuclein family members, including α-synuclein (also designated NACP for non-β Amyloid component) and β-synuclein, are predominantly expressed in the brain and are speculated to be involved in synaptic regulation and neuronal plasticity. α-synuclein is localized to neuronal cell bodies and synapses. α-synuclein was first identified as a component of Alzheimer’s disease amyloid plaques. Abnormal platelet function in Alzheimer’s disease has been demonstrated. During megakaryocytic differentiation α-synuclein has been found to be upregulated, while β-synuclein is downregulated, indicating that coordinate expression of synucleins may be important during hematopoetic cell differentiation. A mutant form of α-synuclein has been found in patients with early onset Parkinson’s disease. Alternative Name :
Alpha synuclein , Alpha-synuclein , Alpha-synuclein, isoform NACP140 , alphaSYN , PARK 1 , PARK 4 , PARK1 , PARK4 , Parkinson disease (autosomal dominant, Lewy body) 4 , Parkinson disease familial 1 , PD 1 , PD1 , SNCA , Snca synuclein, alpha (non A4 component of amyloid precursor) , Synuclein alpha 140 , Synuclein alpha , Swiss-Prot :
P37840 Product :
1 mg/ml in DI water. Purification&Purity :
Synthetic peptide p-Synuclein-α (S129). (Note: the amino acid sequence is proprietary). The purity is > 98%. Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
This peptide can be used with studies using BS4361 p-Synuclein-α (S129) pAb.
Blocking peptide available as BS4361PP